Boehringer Ingelheim Press Releases

Boehringer Ingelheim microParts inaugurates new inhaler factory

New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin

ERS COPD Research Award 2010
Sponsored by Boehringer Ingelheim

FDA Committee Unanimously Recommends Approval of Dabigatran Etexilate for Stroke Prevention in Atrial Fibrillation

Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer

HIV-1 patients with an undetectable viral load can switch to VIRAMUNE® regardless of their CD4 count

Combination therapy of telmisartan and amlodipine provides significantly better blood pressure lowering than either agent alone

A new era for patients with atrial fibrillation - Dabigatran etexilate at the forefront

New Global Campaign Aims to Prevent As Many As 1 Million Atrial Fibrillation-Related Strokes

Sub-Analysis Shows Primary Benefits seen with RE-LY® are Independent of Level of Centre-Based International Normalized Ratio Control

Boehringer Ingelheim celebrates its 125-year
existence and looks to the future with confidence

Boehringer Ingelheim inaugurates the Shanghai “Center of Competence” as a part of the company’s EUR 100 million expansion project in China

Boehringer Ingelheim successfully concluded the purchase of Fort Dodge cattle vaccines for its Mexican business

Turnover and profit expectations fulfilled for first half-year results / New growth expected from innovative medicines

European Committee for Medicinal Products for Human Use (CHMP) adopts Positive Opinion for TWYNSTA®, Boehringer Ingelheim’s new single pill combination hypertension treatment

VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune®) extended release (NVP XR) formulation

First PCV-2 / Mycoplasma hyopneumoniae vaccine combination registered in the European Union

Fekrije Selimi wins Boehringer Ingelheim’s FENS Award 2010 for Exceptional Research in Neuroscience